^
Association details:
| Biomarker: | HER-2 negative |
|---|---|
| Cancer: | Gastroesophageal Junction Adenocarcinoma |
| Drug: | AiTan (rivoceranib) (VEGFR-2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A prospective, randomized, controlled, multicenter, phase III study of apatinib plus concurrent neoadjuvant chemoradiotherapy for Siewert II ，III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction
Excerpt:
...The her-2 negative was detected by immunohistochemistry or fluorescence in situ hybridization; 3. ...
Trial ID:
Source:
Title:
Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction
Excerpt:
...The her-2 negative was detected by immunohistochemistry or fluorescence in situ hybridization; 3....
Trial ID:
More C2 evidence
Source:
Title:
A prospective, multi-center, real-world study of apatinib mesylate in the treatment of gastric cancer
Excerpt:
...Patients with HER2 negative gastric or gastroesophageal junction adenocarcinoma confirmed by histology or cytology; 3. ...
Trial ID:
Source:
Title:
A single arm, exploratory clinical study of irinotecan liposomes combined with apatinib for second-line treatment of advanced HER2 negative gastric cancer patients
Excerpt:
......
Trial ID:
Source:
Title:
A Phase Ib clinical study of SC0011 in combination with apatinib for the treatment of advanced gastric cancer/gastroesophageal junction adenocarcinoma.
Excerpt:
......
Source:
Title:
A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction
Excerpt:
...Confirmed to Siewert II , III of locally advanced adenocarcinoma at gastroesophageal junction and tumor long diameter ≤8 cm by gastroscopy and CT, The her-2 negative was detected by immunohistochemistry; 3....
Trial ID:
Less C2 evidence
Source:
Title:
A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.
Published date:
05/25/2023
Excerpt:
This retrospective study included consecutive patients who received a programmed cell death protein 1 (PD-1) inhibitor plus the VEGFR-2 inhibitor apatinib...histologically-proven, human epidermal growth factor receptor 2 (HER2)-negative G/GEJ cancer....The objective response rate was 15.4% (95% confidence interval [CI] 6.9–28.1), the disease control rate was 61.5% (95% CI 47.0–74.7)...median progression-free survival was 4.2 months (95% CI 2.6–4.8), overall survival was 9.3 months (95% CI 7.9–12.9)....Combination therapy with an anti-PD-1 antibody and apatinib was effective in patients with previously treated, unresectable advanced or metastatic G/GEJ cancer, with a manageable safety profile.
Secondary therapy:
Undisclosed PD-1 inhibitor
DOI:
10.1200/JCO.2023.41.16_suppl.e16048
Source:
Title:
Efficacy and safety of neoadjuvant chemoradiotherapy plus apatinib for patients with locally advanced, HER2-negative, Siewert’s type II-III adenocarcinoma of esophagogastric junction: a single-arm, open-label, phase II trial
Published date:
08/15/2021
Excerpt:
This study aimed to investigate the efficacy and safety of concurrent neoadjuvant chemoradiotherapy (CRT) plus apatinib in treating locally advanced, HER2-negative, Siewert’s type II-III adenocarcinoma of esophagogastric junction (AEG) patients....Thirty patients completed neoadjuvant CRT plus apatinib treatment, and then their treatment response and down-staging rate were assessed. It was observed that no (0%) patients achieved CR, 18 (60.0%) achieved PR, 11 (36.7%) achieved SD, and 1 (3.3%) achieved PD, which results in an ORR of 60.0% and a DCR of 96.7% (Figure 2)....The mean PFS was 31.4 months, with a 95% CI of 28.8-34.0 months. Meanwhile, the 1-year and 2-year PFS rates were 96.7% and 88.1%, respectively (Figure 4A). Regarding OS, the mean OS was 32.5 months, with a 95% CI of 30.4-34.5 months; the 1-year and 2-year OS rates were 100% and 96.6%, respectively (Figure 4B).
Secondary therapy:
Chemotherapy
Trial ID:
Source:
Title:
1427P - A phase II study of neoadjuvant concurrent chemoradiotherapy with apatinib for HER-2 negative Siewert type II and III adenocarcinoma of esophagogastric junction
Published date:
09/14/2020
Excerpt:
Neoadjuvant concurrent CRT and apatinib results in high R0 resection and pCR rates in patients with resectable HER-2 negative AEG with manageable safety.
Trial ID: